The Pfizer and BioNTech mRNA Vaccine for COVID-19 Conferred 95% Protection With a Satisfactory Safety Profile
Pfizer and BioNTech release safety and efficacy data from phase 2/3 trials for their COVID-19 mRNA vaccine.
Respiratory
Inequities Likely to Blame for Racial Disparities of COVID-19
Further research is needed to identify possible interventions that may mitigate the racial disparities seen in COVID-19.
Atrial Fibrillation, Fulminant Myocarditis Observed in Adolescent With COVID-19
Case of a 15-year-old African American girl with COVID-19 who developed atrial fibrillation and fulminant myocarditis.
Cutaneous, Histopathologic Features of COVID-19 in Children Identified
Cutaneous and histopathologic manifestations of COVID-19 infection in a pediatric population are described.
Brensocatib in Bronchiectasis Patients: A Phase 2 Trial
Investigators examined whether brensocatib reduces incidence of exacerbations of bronchiectasis, reduces rate of exacerbations, or changes the concentration of active neutrophil in the sputum from baseline.
IL-6 Inhibitors Associated With Reduced In-Hospital COVID-19 Mortality
Investigators assessed whether interleukin-6 inhibitors reduced the odds of in-hospital COVID-related mortality.
SARS-CoV-2 RNA Viral Load Dynamics and Duration of Shedding
Researchers examined duration of viral RNA shedding and viable virus shedding of SARS-CoV-2 in body fluids and compared SARS-CoV-2, SARS-CoV, and MERS-CoV viral dynamics.
FDA: SARS-CoV-2 Mutations May Impact Molecular Tests
The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.
Patients Treated for Stroke During COVID-19 Pandemic Have Delayed Thrombolysis
Study researchers investigated whether the COVID-19 pandemic potentially contributed to the delay in acute stroke care.
PlasmAr Trial: Convalescent Plasma for COVID-19 Show No Difference in Mortality, Clinical Outcome
Investigators conducted the PlasmAr trial to evaluate the safety and efficacy of convalescent plasma in the treatment of SARS-CoV-2 pneumonia.
-
Loading...
-
Loading...
